Quick Answer
Rapport Therapeutics, Inc. reported Research And Development Expense of $94.79 million for the year ending 2025.
- Rapport Therapeutics, Inc. showed an increase of +55.6% in Research And Development Expense from 2024 to 2025.
- This data is from Rapport Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: $4.72 million | Q3 2023: $7.58 million | Q1 2024: $12.50 million | Q2 2024: $15.69 million | Q3 2024: $15.54 million | Q1 2025: $19.57 million | Q2 2025: $22.68 million | Q3 2025: $22.28 million.
- Over the full 3 years of available data (2023 to 2025), Rapport Therapeutics, Inc.'s Research And Development Expense has grown by 238.5%.
- Historical annual values: Fiscal year 2025: $94.79 million | Fiscal year 2024: $60.94 million | Fiscal year 2023: $28.00 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: